U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Eli Lilly and Company’s LLY stock has declined 5.1% so far this month, despite announcing strong second-quarter results on ...

Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Shares in Novo Nordisk rose as much as 5% in early European trading Monday, regaining some ground after losing more than half of their value over the past year.

Blockbuster weight loss jabs relied on by millions not be the quick fix many believe it to be, experts warn, as users pil on ...